Bristol-Myers Squibb Co. - Bathi resik saben saham (EPS TTM) BMY

Bristol-Myers Squibb (BMY) efficiency relies on R&D and oncology integration to combat the patent cliff. The 12-month net income per share history demonstrates the market reaction, where the 4.48 mark serves as a key metric. Revenue growth is pursued through the acquisition of biotech startups, yet pressure from the loss of exclusivity for Eliquis and Revlimid maintains risks of margin compression.
Rincian analitis perusahaan Bristol-Myers Squibb

Staff optimization and the restructuring of the R&D core at Bristol-Myers Squibb (BMY) directly impact operational efficiency, which is reflected in the trend of net income per share. This trailing 12-month net income per share neutralizes one-time accounting distortions, allowing investors to assess the business's actual ability to generate capital and determine the risk of overpaying when purchasing the asset.